Akebia Therapeutics (STU:AX9) Cyclically Adjusted FCF per Share: €-0.75 (As of Mar. 2026)


STU:AX9 Akebia Therapeutics Inc STU:AX9
46 GF Score
Price €1.13
GF Value €1.12
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Cyclically Adjusted FCF per Share?

Akebia Therapeutics STU:AX9 +4.31% 46 Cyclically Adjusted FCF per Share is €-0.75 as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 46/100 and a GF Value™ of €1.12 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Akebia Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.069. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.75 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 20.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Akebia Therapeutics was 20.10% per year. The lowest was 20.10% per year. And the median was 20.10% per year.

As of today (2026-07-07), Akebia Therapeutics's current stock price is €1.1255. Akebia Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.75. Akebia Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Akebia Therapeutics  (STU:AX9) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Akebia Therapeutics Cyclically Adjusted FCF per Share Related Terms


Akebia Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Cyclically Adjusted FCF per Share Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.23 -1.40 -1.01 -0.65

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.92 -0.81 -0.75 -0.65 -0.75

STU:AX9 vs TKNO, ORGO, SIGA: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:AX9
46GF Score
Akebia Therapeutics Inc STU:AX9
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akebia Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.069/330.2130*330.2130
=-0.069

Current CPI (Mar. 2026) = 330.2130.

Akebia Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.664 241.018 -0.910
201609 -0.694 241.428 -0.949
201612 2.368 241.432 3.239
201703 -0.240 243.801 -0.325
201706 0.528 244.955 0.712
201709 -0.987 246.819 -1.320
201712 -0.300 246.524 -0.402
201803 -0.344 249.554 -0.455
201806 0.133 251.989 0.174
201809 -0.192 252.439 -0.251
201812 -0.942 251.233 -1.238
201903 -1.057 254.202 -1.373
201906 -0.302 256.143 -0.389
201909 0.065 256.759 0.084
201912 -0.696 256.974 -0.894
202003 -0.631 258.115 -0.807
202006 0.241 257.797 0.309
202009 -0.161 260.280 -0.204
202012 -0.174 260.474 -0.221
202103 -0.387 264.877 -0.482
202106 -0.325 271.696 -0.395
202109 -0.275 274.310 -0.331
202112 -0.318 278.802 -0.377
202203 -0.110 287.504 -0.126
202206 -0.152 296.311 -0.169
202209 0.186 296.808 0.207
202212 -0.281 296.797 -0.313
202303 -0.089 301.836 -0.097
202306 0.018 305.109 0.019
202309 -0.036 307.789 -0.039
202312 -0.011 306.746 -0.012
202403 -0.087 312.332 -0.092
202406 -0.045 314.175 -0.047
202409 -0.029 315.301 -0.030
202412 -0.019 315.605 -0.020
202503 -0.052 319.799 -0.054
202506 0.071 322.561 0.073
202509 0.087 324.800 0.088
202512 0.075 324.054 0.076
202603 -0.069 330.213 -0.069

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.75 mean?
Akebia Therapeutics (STU:AX9) has a Cyclically Adjusted FCF per Share of €-0.75 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Cyclically Adjusted FCF per Share too high?
Akebia Therapeutics' current Cyclically Adjusted FCF per Share is €-0.75. Overall, Akebia Therapeutics has a GF Score™ of 46/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Cyclically Adjusted FCF per Share compare to TKNO and ORGO?
Akebia Therapeutics' Cyclically Adjusted FCF per Share of €-0.75 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Cyclically Adjusted FCF per Share is €-0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.12, compared to a current price of €1.13 — trading 0.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.75. Akebia Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Cyclically Adjusted FCF per Share is €-0.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of €1.13 is trading 0.5% above its estimated GF Value™ of €1.12. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

  • Cyclically Adjusted FCF per Share: €-0.75
  • GF Value™: €1.12 vs. price of €1.13 (0.5% above fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
46GF Score

Get the complete analysis for STU:AX9

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.13
Price
€1.12
GF Value